Short Interest in Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) Rises By 26.7%

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 615,400 shares, a growth of 26.7% from the December 15th total of 485,600 shares. Based on an average trading volume of 100 shares, the days-to-cover ratio is presently 6,154.0 days.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RCDTF. Barclays upgraded Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a report on Tuesday, October 22nd. Royal Bank of Canada upgraded shares of Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

RCDTF stock remained flat at $55.54 during midday trading on Friday. Recordati Industria Chimica e Farmaceutica has a 1-year low of $52.25 and a 1-year high of $52.25. The firm has a fifty day simple moving average of $53.19 and a two-hundred day simple moving average of $52.47. The firm has a market capitalization of $11.46 billion, a price-to-earnings ratio of 27.77 and a beta of 0.30.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.